NeuroOne Medical Technologies (NMTC) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported product revenue of $2.9 million in Q1 2026, down from $3.3 million in Q1 2025, but up 5.5% from $2.7 million in Q4 2025 [11][12] - The net loss for Q1 2026 was $1.4 million, or a loss of $0.03 per share, compared to a net income of $1.8 million, or $0.06 per share, in Q1 2025 [13] - Cash and cash equivalents as of December 31, 2025, were $3.6 million, down from $6.6 million as of September 30, 2025 [13][14] Business Line Data and Key Metrics Changes - The OneRF brain ablation system saw nearly half of all ablations performed since its launch in Q1 2026, indicating strong market adoption [4] - The OneRF trigeminal nerve ablation system initiated a limited commercial launch in Q1 2026, with nine patients treated across three centers, all reporting pain relief [5][21] Market Data and Key Metrics Changes - The company is working towards receiving ISO 13485 certification to facilitate international commercialization of its technology [5] - The company is in discussions with strategic partners for potential licensing of the trigeminal nerve ablation technology [7][22] Company Strategy and Development Direction - The company projects fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025 [3] - The company is establishing a registry to capture patient outcomes from the OneRF brain ablation system, aiming to enroll the first patient by the end of Q3 2026 [4] - The company is accelerating its drug delivery program, expecting devices for commercial use in investigational studies by Q3 2026, six months ahead of schedule [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued positive momentum from fiscal year 2025 and the progress across various programs [3][16] - The company is prepared to commercialize the trigeminal nerve ablation technology independently if strategic discussions do not conclude favorably [22] Other Important Information - The company appointed Jason Mills to its board of directors, who brings significant experience in strategy and business development [10] - The company had no debt outstanding as of December 30, 2025, and is funded through fiscal 2026 [14][15] Q&A Session Summary Question: Update on trigeminal nerve ablation cases and interest from Zimmer - The nine cases were performed at three centers, with all patients reporting pain relief. Discussions with strategic partners are ongoing, but the company is prepared to commercialize independently if necessary [21][22] Question: Expectations for operating expenses for the rest of the year - SG&A expenses are expected to remain flat, while R&D expenses may fluctuate based on project phases [25] Question: Clinical feedback from neurologists or surgical teams - Feedback indicates success in reducing seizures or eliminating them, with procedures being performed at patients' bedsides [33][35] Question: Sales and marketing responsibilities with Zimmer - Zimmer is responsible for all marketing and sales costs, while the company provides training and field support [37] Question: Revenue breakdown for Q1 - Most revenue was from restocking, following the initial stocking order in Q1 2025 [38]